Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort-Reference-Cited by-同舟云学术

Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort

Published:2012-01 Issue:1 Volume:56 Page:234-240
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Armstrong Matthew J.,Houlihan Diarmaid D.,Bentham Louise,Shaw Jean C.,Cramb Robert,Olliff Simon,Gill Paramjit S.,Neuberger James M.,Lilford Richard J.,Newsome Philip N.

Publisher

Elsevier BV

Subject

Hepatology

Reference31 articles.

1. The prevalence and etiology of elevated aminotransferase levels in the United States;Clark;Am J Gastroenterol,2003

2. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study;Bedogni;Hepatology,2005

3. Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units;Caballería;BMC Gastroenterol,2007

4. Hamaguchi M, Kojima T, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005.

5. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity;Browning;Hepatology,2004

Cited by 254 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approach to Abnormal Liver Biochemistries in the Primary Care Setting;Cureus;2024-03-20

2. Steatosis regression assessed by cap after Vitamin ‘D’ supplementation in NAFLD patients with Vitamin ‘D’ deficiency;European Journal of Gastroenterology & Hepatology;2024-01

3. Insulin resistance and cardiovascular risk factors in childhood metabolic dysfunction-associated steatotic liver disease;Cukurova Medical Journal;2023-09-30

4. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective;Journal of Clinical Medicine;2023-09-26

5. Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study;Diagnostic and Prognostic Research;2023-09-12